EVALUATION OF HEPATOCYTE GROWTH-PROMOTING FACTORS IN TREATING 1687 CASES OF FULMINANT HEPATITIS

Fulminant hepatitis is a serious and complex disease with high mortality. In recent years, hepatocyte growth-promoting factors (pHGF), developed on the basis of fetal liver cell injection, has been jointly used as a comprehensive therapy for fulminant hepatitis. The following is a report of the results of using pHGF for the treatment of 1687 cases of fulminant hepatitis (with 1196 controls).

促肝细胞生长素对肝炎患者外周血sIL-2R的影响

目的 探讨促肝细胞生长素（PHGF）对慢性肝炎及重症肝炎患者细胞免疫功能的影响。方法 对102例慢性肝炎及重症肝炎住院患者给予PHGF治疗前后血清可溶性白细胞介素Ⅱ受体（sIL-2R）变化与同样数目病人常规治疗前后血清sIL-2R变化对比。结果 PHGF治疗组sIL-2R水平较治疗前明显降低（P〈0．01），且与对照组治疗后sIL-2R水平对比有显著差异（P〈0.05～0．01）。结论 PHGF在慢性肝炎、重症肝炎治疗过程中可以调节机体免疫状态和减轻机体免疫损伤，从而减轻对肝细胞损害程度，有利于肝细胞修复、再生和肝功能的恢复，且对重症肝炎疗效显著。